OncoCyte Corporation focuses on the development and commercialization of novel and non-invasive blood and urine (liquid biopsy) diagnostic tests for the early detection of cancer. The company is developing diagnostic tests using genetic and protein markers expressed in various types of cancer. It develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancer. The company was founded in 2009 and is based in Alameda, California. OncoCyte Corporation is a subsidiary of BioTime, Inc.
Industry, Sector and Symbol
Industry Biotechnology
Sub-IndustryN/A
SectorMedical
SymbolNYSEAMERICAN:OCX
CUSIPN/A
Phone+1-510-7750515
Debt
Debt-to-Equity RatioN/A
Current RatioN/A
Quick RatioN/A
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book ValueN/A
Price / BookN/A
Profitability
EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-404.76%
Return on Assets-209.93%
Miscellaneous
EmployeesN/A
Outstanding Shares39,400,000
OncoCyte (NYSEAMERICAN:OCX) Frequently Asked Questions
What is OncoCyte's stock symbol?
OncoCyte trades on the New York Stock Exchange (NYSE)AMERICAN under the ticker symbol "OCX."
How were OncoCyte's earnings last quarter?
OncoCyte Corp (NYSEAMERICAN:OCX) posted its quarterly earnings data on Tuesday, May, 15th. The biotechnology company reported ($0.12) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.13) by $0.01. View OncoCyte's Earnings History.
When is OncoCyte's next earnings date?
Are investors shorting OncoCyte?
OncoCyte saw a decrease in short interest in the month of May. As of May 31st, there was short interest totalling 619,924 shares, a decrease of 11.9% from the May 15th total of 703,376 shares. Based on an average daily volume of 45,906 shares, the short-interest ratio is presently 13.5 days. Approximately 3.3% of the company's stock are sold short. View OncoCyte's Current Options Chain.
Who are some of OncoCyte's key competitors?
Some companies that are related to OncoCyte include ABcann Global (ABCN), Horizon Discovery Group (HZD), IMV (IMV), Faron Pharmaceuticals Oy (FARN), Bionomics (BNO), Fennec Pharmaceuticals (FRX), ImmunoVaccine (IMMVF), Arix Bioscience (ARIX), Mereo BioPharma Group (MPH), Ampio Pharmaceuticals (AMPE), Immupharma (IMM), Verona Pharma (VRP), Emblem (EMC), Cannabics Pharmaceuticals (CNBX) and Oxford Biodynamics (OBD).
Who are OncoCyte's key executives?
OncoCyte's management team includes the folowing people:
- Mr. William Annett, Pres, CEO & Director (Age 64)
- Dr. Kristine C. Mechem Ph.D., VP of Marketing & Planninng
- Dr. Lyndal K. Hesterberg Ph.D., Sr. VP of R&D
- Mr. Mitchell S. Levine, Chief Financial Officer
- Mr. Michael G. Vicari, VP of Sales
Has OncoCyte been receiving favorable news coverage?
Media headlines about OCX stock have trended positive this week, according to Accern Sentiment Analysis. The research firm rates the sentiment of press coverage by monitoring more than twenty million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. OncoCyte earned a news impact score of 0.28 on Accern's scale. They also gave media coverage about the biotechnology company an impact score of 46.34 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days.
How do I buy shares of OncoCyte?
Shares of OCX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is OncoCyte's stock price today?
One share of OCX stock can currently be purchased for approximately $2.30.
How big of a company is OncoCyte?
OncoCyte has a market capitalization of $67.57 million.
How can I contact OncoCyte?
OncoCyte's mailing address is 1010 Atlantic Ave Ste 102, ALAMEDA, CA 94501-1147, United States. The biotechnology company can be reached via phone at +1-510-7750515.
MarketBeat Community Rating for OncoCyte (OCX)
MarketBeat's community ratings are surveys of what our community members think about OncoCyte and other stocks. Vote "Outperform" if you believe OCX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCX will underperform the S&P 500 over the long term. You may vote once every thirty days.
